Skip to Content
Merck
All Photos(1)

Documents

14-792-M

Sigma-Aldrich

PI 3-Kinase (p110α(H1047R)/p85α), 10 µg

Complex of N-terminal 6His-tagged recombinant human p110α full length, containing the mutation H1047R & untagged, recombinant, human p85α full length.

Synonym(s):

Active PI 3-Kinase Protein, PI 3-Kinase p110α/p85α

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352200
eCl@ss:
32160405
NACRES:
NA.32

biological source

human

Quality Level

recombinant

expressed in baculovirus infected Sf21 cells

product line

Upstate®

form

liquid

specific activity

(For Specific Activity data, refer to the Certificate of Analysis for individual lots of this enzyme.)

mol wt

Mw 125 kDa (p110α(H1047R))
Mw 84 kDa (p85α)

purified by

(Ni2+/NTA-agarose)

species reactivity

human

manufacturer/tradename

Upstate®

color

colorless

solubility

water: soluble

accession no.

U79143

application(s)

life science and biopharma

Gene Information

human ... PIK3CA(5290)

General description

Research area: Cell Signaling

Complex of N-terminal 6His-tagged recombinant human p110α full length, containing the mutation H1047R, and untagged, recombinant, human p85α full length. The H1047R substitution is a somatic mutation in p110α that has been associated with tumours of the colon, stomach, breast, and brain. PI3Ks are categorized into three classes, namely class I, II, and III, based on their structural characteristics, substrate specificities, and the nature of lipid end-products. Class IA PI3Ks are composed of heterodimers that include a p110 catalytic subunit and a p85 regulatory subunit. In mammals, PIK3CA, PIK3CB, and PIK3CD, encode the p110 catalytic isoforms: p110α, p110β, and p110δ, respectively.

Biochem/physiol Actions

PI3 kinases play a critical role in various cellular processes such as cell survival, proliferation, differentiation, apoptosis, DNA repair, angiogenesis, cellular metabolism, and motility. PI3Ks can activate the serine/threonine kinase AKT and other downstream effector pathways by transmitting signals from growth factors and cytokines into intracellular messages. Genetic mutation in p110α is observed in breast, pancreatic, colon, liver, and lung cancers.Combined in vitro and in vivo studies have shown that this mutation confers higher lipid kinase activity than wild type, and can induce oncogenic transformation.

Packaging

Also available in 10 μg size and in bulk
Also available in 250μg size --call for pricing and availability and reference catalog number 14-792M when ordering the 250μg size.

Target description

PI3Kα/p85α

Physical form

50 mM Tris/HCl pH8.0, 300 mM NaCl, 0.1 mM EGTA, 0.03% Brij-35, 270 mM sucrose, 0.2 mM PMSF, 1 mM benzamidine, 0.1% 2-mercaptoethanol. Frozen solution.

Other Notes

For Specific Activity data, refer to the Certificate of Analysis for individual lots of this enzyme.

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Hazard Classifications

Skin Sens. 1

Storage Class Code

10 - Combustible liquids

WGK

WGK 1

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer
Liu P, et al.
Nature Reviews Drug Discovery, 8(8), 627?644-627?644 (2009)
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
Akinleye A, et al.
Journal of Hematology & Oncology, 6 (2013)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service